TY - JOUR
T1 - Targeting resistance to targeted therapies
T2 - Combating a resilient foe
AU - Devarakonda, Siddhartha
AU - Govindan, Ramaswamy
N1 - Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/12/15
Y1 - 2018/12/15
N2 - While the advent of third-generation therapies has dramatically changed the treatment paradigm for EGFR-mutated lung cancer, resistance to these agents inevitably emerges. Understanding resistance mechanisms and their genomic underpinnings is crucial for developing innovative strategies that are capable of meaningfully prolonging patient survival.
AB - While the advent of third-generation therapies has dramatically changed the treatment paradigm for EGFR-mutated lung cancer, resistance to these agents inevitably emerges. Understanding resistance mechanisms and their genomic underpinnings is crucial for developing innovative strategies that are capable of meaningfully prolonging patient survival.
UR - http://www.scopus.com/inward/record.url?scp=85058470963&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-3178
DO - 10.1158/1078-0432.CCR-18-3178
M3 - Article
C2 - 30352903
AN - SCOPUS:85058470963
SN - 1078-0432
VL - 24
SP - 6112
EP - 6114
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 24
ER -